View Item 

Show simple item record

Cost-Effectiveness of Migraine Treatment: A Commentary
dc.contributor.authorSmith, Dean G.en_US
dc.date.accessioned2010-06-01T22:01:21Z
dc.date.available2010-06-01T22:01:21Z
dc.date.issued2003-07en_US
dc.identifier.citationSmith, Dean G. (2003). "Cost-Effectiveness of Migraine Treatment: A Commentary." Value in Health 6(4): 436-437. <http://hdl.handle.net/2027.42/75050>en_US
dc.identifier.issn1098-3015en_US
dc.identifier.issn1524-4733en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/75050
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=12859584&dopt=citationen_US
dc.format.extent42380 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Science Incen_US
dc.rights2003 ISPORen_US
dc.titleCost-Effectiveness of Migraine Treatment: A Commentaryen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelMedicine (General)en_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity of Michigan, Ann Arbor, MI, USA; and Massey University, Albany, New Zealanden_US
dc.identifier.pmid12859584en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/75050/1/j.1524-4733.2003.64005.x.pdf
dc.identifier.doi10.1046/j.1524-4733.2003.64005.xen_US
dc.identifier.sourceValue in Healthen_US
dc.identifier.citedreferenceLipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001; 41: 646 – 57.en_US
dc.identifier.citedreferenceGoadsby PJ, Lipton RB, Ferrari MD. Migraine—current understanding and treatment. N Engl J Med 2002; 346: 257 – 70.en_US
dc.identifier.citedreferenceWells N, Hettiarachchi J, Drummond M, et al. A cost-effectiveness analysis of eletriptan 40 mg and 80 mg versus sumatriptan 50 mg and 100 mg in the acute treatment of migraine. Value Health 2003; 6: 438 – 47.en_US
dc.identifier.citedreferenceAdelman JU, Lipton RB, Ferrari MD, et al. Comparison of rizatriptan and other triptans on stringent measures of efficacy. Neurology 2001; 57: 1377 – 83.en_US
dc.identifier.citedreferenceTerwindt GM, Ferrari MD, Tijhuis M, et al. The impact of migraine on quality of life in the general population: the GEM study. Neurology 2000; 55: 624 – 9.en_US
dc.identifier.citedreferenceCohen JA, Beall D, Beck A, et al. Sumatriptan treatment for migraine in a health maintenance organization: economic, humanistic, and clinical outcomes. Clin Ther 1999; 21: 190 – 204.en_US
dc.identifier.citedreferenceLegg RF, Sclar DA, Nemec NL, et al. Cost benefit of sumatriptan to an employer. J Occup Environ Med 1997; 39: 652 – 7.en_US
dc.identifier.citedreferenceFerrari MD, Roon KI, Lipton RB, et al. Oral triptans (serotonin 5-HT (1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001; 358: 1668 – 75.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1524-4733.2003.64005.x.pdf
Size:
41.38KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.